BR112021000455A2 - Suporte de peptídeo de automontagem - Google Patents

Suporte de peptídeo de automontagem Download PDF

Info

Publication number
BR112021000455A2
BR112021000455A2 BR112021000455-6A BR112021000455A BR112021000455A2 BR 112021000455 A2 BR112021000455 A2 BR 112021000455A2 BR 112021000455 A BR112021000455 A BR 112021000455A BR 112021000455 A2 BR112021000455 A2 BR 112021000455A2
Authority
BR
Brazil
Prior art keywords
peptide
seq
oligomer
hapten
conjugate
Prior art date
Application number
BR112021000455-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Keith Douglas Miller
Original Assignee
Hexamer Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexamer Therapeutics, Inc. filed Critical Hexamer Therapeutics, Inc.
Publication of BR112021000455A2 publication Critical patent/BR112021000455A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021000455-6A 2018-07-12 2019-07-12 Suporte de peptídeo de automontagem BR112021000455A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697132P 2018-07-12 2018-07-12
US62/697,132 2018-07-12
PCT/US2019/041601 WO2020014609A2 (en) 2018-07-12 2019-07-12 Self-assembling peptide scaffold

Publications (1)

Publication Number Publication Date
BR112021000455A2 true BR112021000455A2 (pt) 2021-04-06

Family

ID=69142622

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021000455-6A BR112021000455A2 (pt) 2018-07-12 2019-07-12 Suporte de peptídeo de automontagem

Country Status (12)

Country Link
US (2) US12458692B2 (https=)
EP (2) EP4218928A3 (https=)
JP (2) JP2021531337A (https=)
KR (1) KR20210065086A (https=)
CN (1) CN112512552B (https=)
AU (2) AU2019300038C1 (https=)
BR (1) BR112021000455A2 (https=)
CA (1) CA3105706A1 (https=)
MA (1) MA52591A (https=)
MX (1) MX2021000444A (https=)
WO (1) WO2020014609A2 (https=)
ZA (1) ZA202100952B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7677953B2 (ja) * 2019-09-12 2025-05-15 ヘキサマー・セラピューティクス・インコーポレイテッド 前立腺癌処置のための免疫治療薬
US20230346920A1 (en) * 2020-05-04 2023-11-02 Hexamer Therapeutics, Inc. Vaccines against viral pathogens

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432260A (en) * 1991-05-03 1995-07-11 Washington University High affinity mannose receptor ligands
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
EP1237930B1 (en) 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Chimeric amyloid beta peptides
US8575070B2 (en) 2006-02-20 2013-11-05 Phylogica Limited Methods of constructing and screening libraries of peptide structures
WO2009030780A2 (en) * 2007-09-07 2009-03-12 Complix Nv Non-natural proteinaceous scaffold made of three non-covalently associated peptides
WO2009134339A2 (en) * 2008-04-29 2009-11-05 Monsanto Technology, Llc Genes and uses for plant enhancement
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
WO2013009971A1 (en) * 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Detection and screening method and materials useful in performance thereof
WO2014126828A1 (en) * 2013-02-15 2014-08-21 Merck Sharp & Dohme Corp. Novel ph-switchable peptides for membrane insertion and pore formation
CA2959201C (en) * 2013-09-16 2021-06-01 The University Of Queensland Silica micro- and nano-capsules and methods for making them
WO2015164798A1 (en) 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
AU2016419048B2 (en) * 2016-08-11 2024-02-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds

Also Published As

Publication number Publication date
AU2023202175A1 (en) 2023-05-04
CN112512552A (zh) 2021-03-16
WO2020014609A4 (en) 2020-04-16
US12458692B2 (en) 2025-11-04
CN112512552B (zh) 2024-10-22
EP3826661A4 (en) 2022-08-31
ZA202100952B (en) 2023-10-25
AU2019300038B2 (en) 2023-01-12
AU2019300038C1 (en) 2024-01-04
JP2021531337A (ja) 2021-11-18
US20260061049A1 (en) 2026-03-05
EP4218928A3 (en) 2023-12-13
MX2021000444A (es) 2021-05-27
CA3105706A1 (en) 2020-01-16
WO2020014609A3 (en) 2020-02-20
MA52591A (fr) 2021-06-02
EP4218928A2 (en) 2023-08-02
EP3826661A2 (en) 2021-06-02
JP2024036461A (ja) 2024-03-15
US20210268105A1 (en) 2021-09-02
WO2020014609A2 (en) 2020-01-16
KR20210065086A (ko) 2021-06-03
AU2019300038A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
Bruun et al. Engineering a rugged nanoscaffold to enhance plug-and-display vaccination
US20260061049A1 (en) Self-assembling peptide scaffold
Moyle et al. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines
JP7677953B2 (ja) 前立腺癌処置のための免疫治療薬
CN113329762A (zh) 用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位
BR112012024872B1 (pt) Composições farmacêuticas compreendendo um polipeptídeo contendo pelo menos um motivo cxxc e antígenos heterólogos e seus usos
US20100143396A1 (en) Method for Preparing a Covalently Cross Linked Oligomer of Amyloid Beta Peptides
US20230346920A1 (en) Vaccines against viral pathogens
Tang et al. Facile and Modular Pipeline for Protein-Specific Antibody Customization
US20240226254A9 (en) Vaccine for therapeutic or prophylactic treatment of myasthenia gravis
JP2024510908A (ja) ペプチド抗原用の担体タンパク質
US20240091346A1 (en) Epstein barr virus vaccines
US20260069676A1 (en) Peptide-loaded antigen presenting cell-derived extracellular blebs as a molecularly targeted vaccine
CN115916253A (zh) 半抗原化冠状病毒刺突蛋白